11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Brent sell
Period: 26.12.2025 Expectation: 210 pips
Supply glut limits Brent crude growth
Yesterday at 11:26 AM 15
Period: 02.01.2026 Expectation: 1000 pips
AUDCAD eyes another move from range floor to ceiling
Yesterday at 09:29 AM 24
Period: 31.12.2025 Expectation: 180 pips
EURUSD selloff targets 1.1700
Yesterday at 08:54 AM 23
Period: 26.12.2025 Expectation: 870 pips
GBPUSD ignores BoE comments and stays in consolidation
Yesterday at 06:00 AM 18
Period: 28.02.2026 Expectation: 20000 pips
Correction may push BTCUSD down to $66,000
Yesterday at 04:42 AM 18
Period: 25.12.2025 Expectation: 20000 pips
Investing in ETHUSD on confirmed bounce from key support
18 December 2025 58
Go to forecasts